Recent 8-K filings for LONA

• May 7, 2026, 7:59 PM ET earnings materiality 0.75 negative item 2.02item 9.01 ◈ Earnings Releases

  LeonaBio Q1 2026 net loss $32.9M ($1.73/share); cash burn $20.9M; ELAINE-3 enrollment target Q4 2026

  Net loss of $32.9M ($1.73 per share) vs $9.1M ($2.34) in Q1 2025, driven by higher R&D spend.

• March 31, 2026, 7:59 PM ET M&A materiality 0.75 neutral item 9.01item 2.01item 1.01

  LeonaBio files amended 8-K on Sermonix license, provides ELAINE-3 cost and timeline update

  SEC granted waiver from providing Sermonix financial statements; license deal treated as business acquisition under Regulation S-X.

• March 26, 2026, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 7.01item 9.01 ◈ Earnings Releases

  LeonaBio reports FY2025 net loss $105.6M; acquires Phase 3 lasofoxifene, raises $90M

  Net loss of $105.6M ($24.70 per share) for FY2025 vs $96.9M loss in FY2024; R&D expenses rose to $85.6M on lasofoxifene license costs.

• March 19, 2026, 7:59 PM ET other material materiality 0.75 neutral item 5.02item 5.07item 8.01item 9.01

  LeonaBio shareholders approve 2026 equity plan, 4x authorized share increase, and Sermonix warrant exercise

  Authorized common shares increased from 90M to 400M; total capital stock from 190M to 500M.

• December 18, 2025, 6:59 PM ET M&A materiality 0.85 positive item 1.01item 3.02item 7.01item 8.01item 9.01

  Athira Pharma licenses lasofoxifene rights, raises $90M in PIPE financing

  Licensed exclusive rights to oral lasofoxifene from Sermonix and Ligand for $34.9M in equity, plus monthly payments and up to $100M milestones.

• December 18, 2025, 6:59 PM ET M&A materiality 0.85 neutral item 1.01item 3.02item 7.01item 8.01item 9.01

  Athira Pharma raises ~$90M via PIPE and licenses lasofoxifene from Sermonix

  PIPE gross proceeds ~$90M; investors include Commodore, TCGX, Perceptive; priced at $6.35/share with warrants.

• November 6, 2025, 6:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01

  Athira Pharma reports Q3 2025 net loss of $6.6M, cash at $25.2M; exploring strategic alternatives

  Net loss of $6.6M ($1.68 per share) vs $28.7M ($7.46 split-adjusted) in Q3 2024.

• October 3, 2025, 7:59 PM ET regulatory materiality 0.60 positive

  Athira Pharma regains Nasdaq minimum bid price compliance; delisting risk removed

  Received Nasdaq notice on Oct 2, 2025 that closing bid price was $1.00+ for ten consecutive days.

• September 11, 2025, 7:59 PM ET other material materiality 0.60 neutral item 3.03item 5.03item 9.01 ◈ Governance Changes

  Athira Pharma to effect 10-for-1 reverse stock split on Sep 17 to meet Nasdaq minimum bid price

  Effective Sept 17 at 5pm ET; shares start trading split-adjusted on Sep 18 under ticker ATHA.

• August 7, 2025, 7:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01

  Athira Pharma Q2 net loss narrows to $7.0M; cash burn slows; ATH-1105 Phase 1 data support ALS development

  Net loss of $7.0M ($0.18/sh) vs $26.9M ($0.70) in Q2 2024, driven by lower R&D and G&A spend.

• May 9, 2025, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01

  Athira Pharma Q1 net loss narrows to $9.1M; ATH-1105 Phase 1 complete, ALS dosing on track

  Cash, cash equivalents and investments totaled $36.7M as of March 31, 2025, down from $51.3M at year-end 2024.

• April 16, 2025, 7:59 PM ET other material materiality 0.80 negative item 3.01

  Athira Pharma transfers to Nasdaq Capital Market; must regain $1 bid price by Oct 13, 2025

  Approved transfer from Nasdaq Global Select Market to Capital Market effective April 17, 2025.

• February 27, 2025, 6:59 PM ET earnings materiality 0.85 negative item 2.02item 9.01

  Athira Pharma FY2024 net loss $96.9M; cash burn continues; ATH-1105 Phase 1 complete; fosgonimeton paused

  Cash, cash equivalents and investments $51.3M as of Dec 31, 2024, down from $147.4M; net cash used in operations $97.2M.

• November 7, 2024, 6:59 PM ET earnings materiality 0.75 negative item 2.02item 9.01

  Athira Pharma Q3 net loss $28.7M; LIFT-AD missed endpoints; exploring strategic alternatives

  Net loss $28.7M ($0.75/sh) vs $33.0M ($0.87/sh) Q3 2023; cash $68.9M down from $147.4M at Dec 2023.

• October 18, 2024, 7:59 PM ET regulatory materiality 0.75 negative item 3.01item 8.01

  Athira Pharma receives Nasdaq bid price deficiency notice; stock below $1 for 30 days

  Received Nasdaq notice on Oct 16, 2024 for non-compliance with minimum bid price of $1.00.

• October 7, 2024, 7:59 PM ET leadership materiality 0.70 negative item 9.01

  Athira Pharma terminates CFO/CBO and COO/CDO; grants retention equity to CEO and VP Finance

  Andrew Gengos (CFO/CBO) and Rachel Lenington (COO/CDO) terminated Oct 1, 2024; severance payments of $363,750 and $375,000 respectively.

• September 17, 2024, 7:59 PM ET other material materiality 0.85 negative item 2.05item 9.01

  Athira cuts 70% of workforce, pivots to ATH-1105 after LIFT-AD readout

  Workforce reduction of ~70% (49 positions); one-time costs ~$2.8M third-quarter 2024.

• September 3, 2024, 7:59 PM ET other material materiality 0.90 negative item 8.01item 7.01item 9.01

  Athira's Phase 2/3 LIFT-AD trial of fosgonimeton misses primary endpoint; biomarker data mixed

  Primary endpoint GST (p=0.70) and key secondary endpoints ADAS-Cog11 (p=0.35) and ADCS-ADL23 (p=0.61) not met; directionally favored fosgonimeton.

• August 1, 2024, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01

  Athira Pharma Q2 net loss $26.9M; LIFT-AD topline data expected Sept 2024

  Cash, cash equivalents and investments were $91.8M as of June 30, 2024, down from $147.4M at Dec 31, 2023.

• May 17, 2024, 7:59 PM ET litigation materiality 0.65 neutral item 8.01item 9.01

  Athira Pharma obtains preliminary approval for derivative lawsuit settlement with governance reforms

  Court preliminary approval on May 3, 2024; final hearing set for July 18, 2024.

• May 15, 2024, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01 ◈ Earnings Releases

  Athira Pharma Q1 2024 net loss $26.3M ($0.69/share); cash $122.1M; LIFT-AD data H2 2024

  Net loss of $26.3M ($0.69/share) vs $27.8M ($0.73/share) in Q1 2023; operating cash burn $25.8M.

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.90 · Median 0.72 · Most common event earnings

3 positive 8 negative 13 neutral

source · LONA on sec.gov